Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million FinancingPRNewsWire • 10/22/26
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding PathwaysPRNewsWire • 09/22/26
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial ResultsPRNewsWire • 08/14/26
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial ResultsPRNewsWire • 08/13/26
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA TestPRNewsWire • 08/05/26
PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026PRNewsWire • 07/31/26
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026PRNewsWire • 07/30/26
PAVmed Provides Business Update and Reports First Quarter 2026 Financial ResultsPRNewsWire • 05/15/26
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial ResultsPRNewsWire • 05/14/26
Will PAVmed Inc. (PAVM) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 05/08/26
PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026PRNewsWire • 05/01/26
Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026PRNewsWire • 04/30/26
Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common StockPRNewsWire • 04/24/26
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare ConferencePRNewsWire • 04/09/26
PAVM Assigns Joseph Virgilio to Lead Medical Device Portfolio RelaunchZacks Investment Research • 04/07/26
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsPRNewsWire • 03/30/26